Clinical update: Selecting the first-line biologic in moderate-to-severe IBD


Clinicians face the challenge of how to select appropriate first biologic agents for IBD patients

You will learn:
• Current evidence that influences selection of first-line biologic therapy for the treatment of inflammatory bowel disease
• Evidence supporting first-line treatment recommendations for moderate-to-severe Crohn’s disease and moderate-to-severely active ulcerative colitis
• Factors to consider when selecting biologic therapies.

To access this module, please register or login: